ArticleImmuno-oncology technology2025
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.
Article in Immuno-oncology technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sex Differences in Cancer-Associated Thrombosis.International journal of molecular sciences · 2026Review
- Bidirectional regulatory mechanisms and therapeutic prospects of tumor hypercoagulable state and immunosuppressive tumor microenvironment.Oncology reviews · 2026Review
- Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) may increase the incidence of thromboembolisms (TEs). In patients with melanoma, the risk of TE and its association with the disease setting remains largely unknown. This study investigated the incidences of arterial thromboembolism (ATE) and venous thromboembolism (VTE) and associated risk factors in ICI-treated patients with melanoma in the advanced and adjuvant disease settings. Patients and methods: ATE and VTE incidences were retrospectively collected from patients receiving ICI in the advanced (irresectable stage III/IV) or adjuvant (stage III/IV, after complete resection) disease setting until 2 years or after censoring. Associations between characteristics and ATE/VTE were analyzed using the Fine-Gray model, with all-cause death as competing risk. Results: In the advanced disease cohort, 7 (2.2%) and 16 (5.1%) of 315 included patients developed ATE and VTE, respectively. In the adjuvant cohort, 3 (2.1%) and 2 (1.4%) of 143 included patients developed ATE and VTE, respectively. In the advanced cohort, ICI combination therapy was associated with VTE [standardized hazard ration (sHR) 4.42, 95% confidence interval (CI) 1.58-12.38, Conclusions: Both ATE and VTE incidences seem to be modest in patients with melanoma receiving ICI in both disease settings. Patients with higher BMI and who are prescribed ICI combination therapy might be at increased thrombotic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.